All In Biotech

Drug Trial Radar · NCT00178620

Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization

PATCAR Pilot Trial: A Phase 4 Study, Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization

Last checked: Nov 20, 2026Latest source record: Sep 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 390 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

390

Actual

Start

Sep 2003

Primary completion

Dec 2009

Study completion Dec 2009

Sponsor

Lead sponsor
The University of Texas Health Science Center, HoustonAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 15, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The PATCAR study has been designed to test the hypothesis that the strategy of pre-hospital use of a "clot busting" (thrombolytic) drug followed with emergent heart catheterization including stenting of the problematic coronary artery, will result in a lower mortality and reduced repeat heart attack rates. Early identifying and treating heart attacks patients prior to the arriving at the hospital, in those patients who qualify for the "clot busting" drugs will lower the size of the heart attack damage. This smaller heart attack will lead to fewer problems with less repeat heart attacks and death in the future.

Conditions

  • Heart Disease
  • Myocardial Infarction
  • Acute Myocardial Infarction

Interventions

  • Reteplase 10 Units (U) plus a second dose of reteplase 10 UDrug

    Thrombolytic-clot busting drug Retavase IV Bolus, 10 U followed by a second 10U dose

  • Reteplase 10 UDrug

    Thrombolytic-clot busting drug Retavase IV Bolus in one 10U dose

  • Urgent Percutaneous Coronary Intervention (PCI)Procedure

  • Primary Percutaneous Coronary Intervention (PCI)Procedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mortality at 30 DaysTime frame: 30 day

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Memorial Hermann Hospital / The University of Texas HSC

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.